Clearmind Medicine Inc

Clearmind Medicine, Inc. operates as a mineral resource company, which acquires, explores, develops, and operates mineral resource assets in Canada. The company was founded on July 18, 2017 and is headquartered in Toronto, Canada.

Earnings data Q2 2024

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional preparations to facilitate the commencement of the company's clinical trial and engaged a contract research organization (CRO) to provide support for the company.

Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial

Clearmind Medicine (NASDAQ: CMND ) stock is on the rise Wednesday despite a lack of news from the psychedelic medicines company. That includes no recent press releases that give a reason for today's soaring share price.

Why Is Clearmind Medicine (CMND) Stock Up 47% Today?

Clearmind Medicine (NASDAQ: CMND ) stock is taking off on Tuesday despite a lack of news concerning the psychedelics company. There's no new press releases or filings with the Securities and Exchange Commission (SEC) that explain the rise in the stock today.

Why Is Clearmind Medicine (CMND) Stock Up 56% Today?

NEW YORK, NY / ACCESSWIRE / April 10, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND)

Tel Aviv, Israel / Vancouver, Canada, April 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of its United States only public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately US$3.5 million, before deducting placement agent fees and other expenses payable by the Company. The offering consisted of 4,505,718 common shares and pre-funded warrants and 4,505,718 common warrants. The common warrants are immediately exercisable, will expire five years from the date of issuance and have an exercise price of US$0.78 per common share. Each common share (or pre-funded warrant in lieu thereof) was sold together with one common warrant at a combined purchase price of US$0.78 per share (or US$0.779 per pre-funded warrant after reducing US$0.001 attributable to the exercise price of the pre-funded warrants) but were issued separately. The common warrants and pre-funded warrants are not listed on any exchange.

Clearmind Medicine Closes US$3.5 Million Public Offering

Company plans to initiate phase I/ IIa in-human clinical trials in Q2 2023

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D.

The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

Dr. Adi Zuloff-Shani PhD., Clearmind's chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

The conference will stream live on Tuesday, February 28, at 8:30 AM EST

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial") resulted in positive outcomes in relation to treating Major Depressive Disorder (“MDD”).

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Isranalytica 2023 , the A nnual meeting of the Israel Analytical Chemical Society , provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the largest annual analytical chemistry conferences in the world

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine's Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

AUSTIN, TX / ACCESSWIRE / January 4, 2023 / SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc. (NASDAQ:CMND)(CSE:CMND)(FWB:CWY), to discuss the biotech company's use of non-hallucinogenic psychedelic compounds to treat physical and mental health, including addiction. The full interview can be heard at: https://www.smallcapvoice.com/nasdaq-cmnd-audio-interview-with-smallcapvoice-com/.

Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com

Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

NEW YORK, NY / ACCESSWIRE / December 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Clearmind Medicine. Toni had the pleasure of recently conducting the Interview with Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani (NASDAQ:CMND).

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani

U.S. Patent and Trademark Office exten ds protection of Clearmind's   proprietary MEAI and expands its potential market

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) --   Clearmind Medicine Inc.   (Nasdaq, CSE: CMND ) ( FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.

Israeli Based Biotech Company Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Nicholas Kadysh , a former Red Bull Canada and Juul Labs Canada executive , is an expert on regulatory issues

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100.

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)

VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of US$6.50 per share (CAD$8.65), for aggregate gross proceeds of US$7.5 million, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse stock split, which was effective at 5:30 p.m. on September 30, 2022.

News for Clearmind Medicine Inc Stock (CMND)